News

­

CaverStem™ Adult Stem Cell Therapy For Erectile Dysfunction Receives Positive Reception At International Urology Conference

PHOENIX, May 23, 2018 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB:CELZ) announced today completion of its 3 day exhibition at the American Urology Association (AUA) meeting. The Company's presentations where delivered by Dr. Alexander Gershman, Director of The Institute of Advanced Urology at the Cedars-Sinai Medical Tower; Director of Urologic Laparoscopy in the Division of [...]

By |May 23rd, 2018|

“Urologist to the Stars” Dr. Alexander Gershman to attend American Urological Association conference to discuss the CaverStem™ Stem Cell Procedure for Drug Refractory Erectile Dysfunction

PHOENIX and LOS ANGELES, May 8, 2018 /PRNewswire/ -- Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today that Dr. Alexander Gershman will attend the AUA conference on May 19th and 20th with Creative Medical Technology Holdings, Inc. to discuss the CaverStem™ procedure from the perspective of a physician treating patients. Dr. Alexander Gershman, Director [...]

By |May 5th, 2018|

Creative Medical Technology Holdings, Inc. To Unveil Its Patented CaverStem™ Procedure For Erectile Dysfunction At International Urology Conference

PHOENIX, March 26, 2018 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) will be exhibiting it's patented CaverStemTM stem cell procedure for erectile dysfunction at the annual American Urological Association (AUA) conference on May 18-21, 2018 in San Francisco. According to the AUA "Last year's meeting welcomed more than 16,000 attendees from more than 100 [...]

By |March 26th, 2018|

Creative Medical Technology Holdings Announces Commercialization of patented Stem Cell Procedure for Erectile Dysfunction.

Trial Results Support Initiation of Urologist Outreach and Commercialization October 18, 2017 Phoenix, AZ, Creative Medical Technology Holdings (OTCQB – CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company’s patented CaverStem TM procedure. The trial, sponsored by Creative Medical Technology Holdings, was conducted at [...]

By |October 18th, 2017|

Creative Medical Technology Holdings Achieves 100% Patient Enrollment in Caverstem™ Clinical Trial for Stem Cell Treatment of Erectile Dysfunction

Company on Schedule for 2018 Commercialization of its Patented Caverstem™ Procedure to Treat Erectile Dysfunction in Patients who do not Respond to Currently Available Treatments. (August 28, 2017 - Phoenix, AZ) Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today completion of enrollment in the Company’s clinical trial assessing safety and efficacy of [...]

By |August 28th, 2017|

Enrollment Initiated in Caverstem™ Clinical Trial to Evaluate the Safety and Efficacy of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction

December, 15 2015 – Enrollment Initiated in Caverstem™ Clinical Trial to Evaluate the Safety and Efficacy of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction Creative Medical Health, Inc. announced that the first patient has been enrolled in the Caverstem™ Clinical Trial to Evaluate the Safety and Efficacy of Intra-cavernosal [...]

By |December 15th, 2015|

Creative Medical Health, Inc. (CMH) announces selection of PRC Clinical, a contract research organization (CRO) to oversee the Caverstem™ Clinical Trial.

October 10, 2015 – Creative Medical Health, Inc. (CMH) announces selection of PRC Clinical, a contract research organization (CRO) to oversee the Caverstem™ Clinical Trial. “CMH is pleased to announce that PRC Clinical has been awarded the contract to provide study monitoring and management services on our Caverstem™ clinical trial for the treatment of erectile [...]

By |October 10th, 2015|

John F. Wolf, M.D. Human Subjects Committee (Institutional Review Board) Approves Caverstem™ Clinical Trial to Evaluate the Safety and Efficacy of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction

July 23, 2015 – John F. Wolf, M.D. Human Subjects Committee (Institutional Review Board) Approves Caverstem™ Clinical Trial to Evaluate the Safety and Efficacy of Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction Creative Medical Health, Inc. (CMH) announced the John F. Wolf, M.D. Human Subjects Committee has authorized CMH [...]

By |July 23rd, 2015|

Creative Medical Health, Inc. Announces Selection of UCLA/LA BioMed and Dr. Jacob Rajfer to Perform a Clinical Trial on Caverstem™ an Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction

June 10, 2015 – Creative Medical Health, Inc. Announces Selection of UCLA/LA BioMed and Dr. Jacob Rajfer to Perform a Clinical Trial on Caverstem™ an Intra-cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction Clinical Stage Biotechnology Company Announces the Selection of Los Angeles Biomedical Research Institute (LA Biomed) located at [...]

By |June 10th, 2015|

Creative Medical Health, Inc. Announces Caverstem™ Clinical Trial of Intra-Cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction

February 7, 2015 – Creative Medical Health, Inc. Announces Caverstem™ Clinical Trial of Intra-Cavernosal Administration of Non-Expanded Autologous Bone Marrow Cells in Treatment of Erectile Dysfunction Clinical Stage Biotechnology Company Completes the Design of Clinical Trial to Validate Safety and Efficacy of Patented Stem Cell Therapy. Creative Medical Health, Inc. (CMH) announced today it has completed [...]

By |February 7th, 2015|